Adverum Biotechnologies Inc (ADVM)
9.28
-0.27
(-2.83%)
USD |
NASDAQ |
May 10, 16:00
9.28
0.00 (0.00%)
After-Hours: 20:00
Adverum Biotechnologies Total Assets (Quarterly): 173.01M for Dec. 31, 2023
Total Assets (Quarterly) Chart
Historical Total Assets (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 173.01M |
| September 30, 2023 | 196.77M |
| June 30, 2023 | 241.43M |
| March 31, 2023 | 275.58M |
| December 31, 2022 | 308.37M |
| September 30, 2022 | 332.36M |
| June 30, 2022 | 374.96M |
| March 31, 2022 | 407.39M |
| December 31, 2021 | 439.73M |
| September 30, 2021 | 490.58M |
| June 30, 2021 | 526.15M |
| March 31, 2021 | 461.55M |
| December 31, 2020 | 482.57M |
| September 30, 2020 | 507.71M |
| June 30, 2020 | 331.18M |
| March 31, 2020 | 348.60M |
| December 31, 2019 | 222.73M |
| September 30, 2019 | 205.52M |
| June 30, 2019 | 209.88M |
| March 31, 2019 | 221.05M |
| December 31, 2018 | 213.50M |
| Date | Value |
|---|---|
| September 30, 2018 | 225.91M |
| June 30, 2018 | 246.58M |
| March 31, 2018 | 257.16M |
| December 31, 2017 | 201.90M |
| September 30, 2017 | 198.21M |
| June 30, 2017 | 208.58M |
| March 31, 2017 | 221.93M |
| December 31, 2016 | 234.58M |
| September 30, 2016 | 256.57M |
| June 30, 2016 | 264.34M |
| March 31, 2016 | 252.93M |
| December 31, 2015 | 264.32M |
| September 30, 2015 | 273.83M |
| June 30, 2015 | 283.72M |
| March 31, 2015 | 292.69M |
| December 31, 2014 | 161.91M |
| September 30, 2014 | 167.24M |
| June 30, 2014 | 54.79M |
| March 31, 2014 | 51.61M |
| December 31, 2013 | 1.085M |
Total Assets Definition
Assets are a main portion of the balance sheet of a company that measure things that provide economic value. A few examples of assets of a company include cash, inventories, and accounts receivable. From an accounting perspective, the balance sheet equation is Assets = Liabilities + Shareholder's Equity.
Total Assets (Quarterly) Range, Past 5 Years
173.01M
Minimum
Dec 2023
526.15M
Maximum
Jun 2021
344.00M
Average
332.36M
Median
Sep 2022
Total Assets (Quarterly) Benchmarks
| Karyopharm Therapeutics Inc | 240.44M |
| Ardelyx Inc | 342.38M |
| Minerva Neurosciences Inc | 50.51M |
| Arcutis Biotherapeutics Inc | 341.36M |
| 4D Molecular Therapeutics Inc | 339.89M |
Total Assets (Quarterly) Related Metrics
| Total Liabilities (Quarterly) | 89.54M |
| Shareholders Equity (Quarterly) | 83.47M |